# Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

> **NCT03018249** · EARLY_PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

## Interventions

- **DRUG:** Entinostat
- **PROCEDURE:** Hysterectomy
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Medroxyprogesterone Acetate

## Key facts

- **NCT ID:** NCT03018249
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-04-18
- **Final completion:** 2021-03-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018249, "Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03018249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*